AGC Biologics

AGC Biologics was founded in 2017 as a result of the merger between Asahi Glass Co., Ltd. and CMC Biologics. The company has its headquarters in Milan and operates a state-of-the-art manufacturing facility in Bresso. AGC Biologics has a market cap of about $8.7B and employs over 1,000 people worldwide.

AGC Biologics' vision is to be a leading global partner for the development and production of biopharmaceuticals, offering innovative solutions and high-quality services to its clients. The company specializes in mammalian and microbial expression systems, providing a full range of services from cell line development to commercial manufacturing. AGC Biologics has a diverse portfolio of products, including monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and biosimilars.

One of the recent projects that AGC Biologics is involved in is the development of a COVID-19 vaccine candidate in collaboration with ReiThera, a biotech company based in Rome. The vaccine candidate uses a viral vector platform and has shown promising results in preclinical and clinical trials. AGC Biologics is responsible for the scale-up and production of the vaccine at its Bresso site.

AGC Biologics is a company that is committed to delivering excellence and value to its customers, partners, and stakeholders. It is also a company that is constantly evolving and adapting to the changing needs and demands of the biopharmaceutical industry.

Foundation: 2017
Headquarters: Milan, Italy
Website: https://www.agcbio.com/